Education
About Us
Working with TipRanks
Follow Us
Sarepta Therapeutics (CH:AB3A)
:AB3A
AB3A Analyst Ratings
Hold
6 Buy
15 Hold
5 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
AB3A Stock 12 Month Forecast
Average Price Target
CHF18.41
| Highest Price TargetCHF63.31 | Average Price TargetCHF18.41 | Lowest Price TargetCHF3.96 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Leerink Partners
―
Hold
―
Reiterated
10/13/25
William Blair
―
Hold
―
Reiterated
10/13/25
Needham
―
Sell
―
Reiterated
10/13/25
Oppenheimer
CHF29.62
Buy
―
Reiterated
10/09/25
Jefferies
CHF28.02
Buy
―
Reiterated
10/08/25
RBC Capital
CHF11.21→CHF12.81
Hold
―
Reiterated
10/08/25
Mizuho Securities
CHF15.21
Hold
―
Reiterated
10/06/25
Evercore ISI
CHF13.61
Hold
―
Reiterated
09/23/25
Cantor Fitzgerald
CHF11.21
Hold
―
Reiterated
09/22/25
Guggenheim
CHF17.61
Buy
―
Reiterated
09/15/25
Bank of America Securities
CHF12.81
Sell
―
Reiterated
09/15/25
Deutsche Bank
CHF9.61
Sell
―
Reiterated
08/27/25
J.P. Morgan
CHF19.21→CHF14.41
Hold
―
Reiterated
08/26/25
H.C. Wainwright
CHF4
Sell
―
Reiterated
08/25/25
Bernstein
―
Hold
―
Reiterated
08/22/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Leerink Partners
―
Hold
―
Reiterated
10/13/25
William Blair
―
Hold
―
Reiterated
10/13/25
Needham
―
Sell
―
Reiterated
10/13/25
Oppenheimer
CHF29.62
Buy
―
Reiterated
10/09/25
Jefferies
CHF28.02
Buy
―
Reiterated
10/08/25
RBC Capital
CHF11.21→CHF12.81
Hold
―
Reiterated
10/08/25
Mizuho Securities
CHF15.21
Hold
―
Reiterated
10/06/25
Evercore ISI
CHF13.61
Hold
―
Reiterated
09/23/25
Cantor Fitzgerald
CHF11.21
Hold
―
Reiterated
09/22/25
Guggenheim
CHF17.61
Buy
―
Reiterated
09/15/25
Bank of America Securities
CHF12.81
Sell
―
Reiterated
09/15/25
Deutsche Bank
CHF9.61
Sell
―
Reiterated
08/27/25
J.P. Morgan
CHF19.21→CHF14.41
Hold
―
Reiterated
08/26/25
H.C. Wainwright
CHF4
Sell
―
Reiterated
08/25/25
Bernstein
―
Hold
―
Reiterated
08/22/25
Best Analysts Covering Sarepta Therapeutics
1 Month
xxx
Success Rate
24/38 ratings generated profit
Average Return
+7.08%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 63.16% of your transactions generating a profit, with an average return of +7.08% per trade.
3 Months
xxx
Success Rate
22/38 ratings generated profit
Average Return
+7.02%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 57.89% of your transactions generating a profit, with an average return of +7.02% per trade.
1 Year
Success Rate
20/38 ratings generated profit
Average Return
+9.93%
reiterated a buy rating last month
Copying Debjit Chattopadhyay's trades and holding each position for 1 Year would result in 52.63% of your transactions generating a profit, with an average return of +9.93% per trade.
2 Years
xxx
Success Rate
17/38 ratings generated profit
Average Return
+7.88%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 44.74% of your transactions generating a profit, with an average return of +7.88% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
AB3A Analyst Recommendation Trends
Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
50
45
30
18
7
Buy
10
10
7
3
2
Hold
38
79
93
84
39
Sell
1
12
18
18
8
Strong Sell
1
4
8
7
4
total
100
150
156
130
60
Each month's total comprises the sum of three months' worth of ratings.
AB3A Financial Forecast
AB3A Stock Forecast FAQ
What is CH:AB3A’s average 12-month price target, according to analysts?
Based on analyst ratings, Sarepta Therapeutics’s 12-month average price target is 18.41.
What is CH:AB3A’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for CH:AB3A, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Sarepta Therapeutics a Buy, Sell or Hold?
Sarepta Therapeutics has a consensus rating of Hold, which is based on 6 buy ratings, 15 hold ratings and 5 sell ratings.
What is Sarepta Therapeutics’s share price target?
The average share price target for Sarepta Therapeutics is 18.41. This is based on 26 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is CHF63.31 ,and the lowest forecast is CHF3.96. The average share price target represents N/A Increase from the current price of N/A.
The highest analyst share price target is CHF63.31 ,and the lowest forecast is CHF3.96. The average share price target represents N/A Increase from the current price of N/A.
What do analysts say about Sarepta Therapeutics?
Sarepta Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 26 Wall Streets Analysts.
How can I buy shares of Sarepta Therapeutics?
To buy shares of CH:AB3A, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.